U.S. Synthetic Biology Market Size, Share & Forecast 2026–2032

ID: MR-11340 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Synthetic Biology Market
  • ✓Market Size 2024: USD 6.2 billion
  • ✓Market Size 2032: USD 14.9 billion
  • ✓CAGR: 11.6%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Biomanufacturing Capacity Bottleneck Persists: Ginkgo Bioworks and Twist Bioscience anchor a U.S. value chain concentrated in design and DNA tools, while commercial-scale fermentation above 100,000 litres remains scarce domestically. Scale-up contracts flow overseas, leaving BioMADE pilot facilities as the main federal bridge.
FINDING 02
Screening Mandates Favour Incumbents: Conventional wisdom treats the OSTP nucleic acid screening framework as a uniform compliance burden. In practice, screening infrastructure favours scaled firms like Twist Bioscience, which absorb automated sequence checking, squeezing benchtop synthesizers and start-ups out of federally funded procurement.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Screening Compliance Before 2026: Procurement officers and investors should qualify suppliers against the OSTP screening framework and BIOSECURE Act restrictions before the 2026 procurement cycle closes. Firms documenting screening protocols now will capture BioMADE and Defense biomanufacturing contracts, while uncertified competitors lose eligibility.

Synthetic Biology in the U.S.: Market Overview

The U.S. synthetic biology market was valued at USD 6.2 billion in 2024 and is forecast to reach USD 14.9 billion by 2032. Its structure runs across three layers: DNA synthesis and design tools, platform engineering services, and applied products in therapeutics, chemicals, and agriculture. Government funding from the National Science Foundation, the Department of Defense, and the Department of Energy created the early research base, with the National Institutes of Health supplying biomedical infrastructure.

Private capital took the lead after 2015, when venture-backed platform companies such as Ginkgo Bioworks and Twist Bioscience scaled commercial foundries and DNA synthesis output. Executive Order 14081, signed on 12 September 2022, then formalised the state role by directing federal agencies to coordinate a national bioeconomy strategy. Policy has therefore shaped the market's current form: government set the research and security frame, while private firms own most commercial platforms and tools.

Policy-Driven Growth in U.S. Synthetic Biology

Executive Order 14081 directs agencies to expand domestic biomanufacturing and set procurement signals across the bioeconomy, translating directly into federal demand for engineered organisms and bio-based inputs. The National Biotechnology and Biomanufacturing Initiative, which implements the order, sets the agenda agencies use to allocate budgets. Demand grows as agency purchasing and research grants are steered toward platforms that meet the order's supply-chain and security objectives.

The USDA BioPreferred Program, authorised under Section 9002 of the Farm Security and Rural Investment Act of 2002, requires federal agencies to buy designated bio-based products. Its catalogue spans dozens of product categories, opening procurement volume to engineered enzymes and biochemicals. The NSF Regional Innovation Engines programme, created under the CHIPS and Science Act of 2022, awards up to USD 160 million per engine over ten years, funding regional biotech clusters that feed commercial pipelines.

Regulatory Barriers and Compliance Costs

The USDA Animal and Plant Health Inspection Service administers 7 CFR Part 340, which governs field release of organisms modified through genetic engineering. The 2020 SECURE rule, which streamlined notification pathways, was vacated by the U.S. District Court for the Northern District of California in December 2024, restoring the legacy permit process. Developers now face APHIS permit reviews that commonly add six to twelve months to field-trial schedules.

The Environmental Protection Agency regulates intergeneric microorganisms under Section 5 of the Toxic Substances Control Act, as amended by the Frank R. Lautenberg Chemical Safety for the 21st Century Act of 2016. Each new microorganism requires a Microbial Commercial Activity Notice with a 90-day review period, extendable through the agency's risk assessment. Separately, the Federal Select Agent Program, run by CDC and APHIS under 42 CFR Part 73, imposes registration and security costs on any laboratory handling listed pathogens.

Policy-Created Opportunities in the U.S.

The BioPreferred catalogue and Department of Defense procurement create subsidised demand for bio-based chemicals, materials, and enzymes. BioMADE, the Department of Defense Manufacturing Innovation Institute, funds pilot-scale biomanufacturing facilities that small firms can access without building their own plants. Buy American Act and Berry Amendment requirements restrict foreign suppliers in defence procurement, sheltering domestic contract manufacturers able to run regulated fermentation.

The OSTP Framework for Nucleic Acid Synthesis Screening, issued in April 2024, requires federally funded researchers to purchase synthetic DNA only from providers that screen orders against sequences of concern. This creates demand for screening software, sequence databases, and third-party audit services. Providers that certify compliance early gain preferred status with NSF- and NIH-funded laboratories, which account for the largest share of U.S. academic synthetic DNA purchasing.

Regulatory and Policy Environment

The primary legislative frame is the Coordinated Framework for the Regulation of Biotechnology, implemented through the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, the Plant Protection Act of 2000, and TSCA as amended in 2016. FDA's Center for Biologics Evaluation and Research regulates engineered therapeutics through investigational new drug procedures, where a 30-day clinical hold review applies. Key compliance requirements include APHIS permits, EPA notices, institutional biosafety committee approval under the NIH Guidelines, and select agent registration.

The National Security Commission on Emerging Biotechnology published its final report in April 2025, recommending expanded federal biotechnology investment and tighter oversight of biotechnology supply chains. The OSTP screening framework moves into a second, more stringent phase in 2026. Compared with the European Union, whose New Genomic Techniques proposal would ease rules for certain plant edits, the U.S. regime is more fragmented across four agencies, yet it deploys federal capital faster than most peers.

Long-Term Policy Outlook for U.S. Synthetic Biology

The BIOSECURE Act provisions restrict federal contracting with biotechnology companies of concern, shifting DNA synthesis and contract manufacturing volume away from Chinese suppliers such as BGI and WuXi AppTec. Federal laboratories and defence contractors must document supplier origin in procurement files, adding compliance steps to every purchase order through 2032.

APHIS is expected to re-propose its Part 340 rule following the court vacatur, and TSCA risk evaluation procedures will set the pace for microbial notices. By 2032 the market will shift from grant-funded pilots toward procurement-backed commercial scale, with BioMADE and NSF Engines facilities supplying the fermentation capacity the U.S. currently lacks.

Market at a Glance

MetricValue
Market Size 2024USD 6.2 billion
Market Size 2032USD 14.9 billion
Growth Rate (CAGR)11.6%
Most Critical Decision FactorAccess to federally funded biomanufacturing capacity and screening compliance
Largest RegionWest Coast (California) and Greater Boston, Massachusetts
Competitive StructureFragmented, with platform leaders and federally anchored consortia

Leading Market Participants

  • Ginkgo Bioworks
  • Twist Bioscience
  • Codexis
  • Solugen
  • LanzaTech
  • Geno
  • Telesis Bio
  • Synthego
  • Ansa Biotechnologies
  • Asimov

Frequently Asked Questions

The Coordinated Framework divides oversight among FDA, USDA APHIS, and EPA, with the Plant Protection Act and TSCA as the principal statutes. Each agency applies its own permit or notification route depending on the product type.
A Microbial Commercial Activity Notice carries a 90-day review period under TSCA Section 5, which EPA can extend. Developers should file before scale-up trials begin.
Federally funded purchasers must buy synthetic DNA from providers that screen orders for sequences of concern. The framework is phased in, with tighter requirements scheduled for 2026.
Yes, through BioMADE, the Department of Defense Manufacturing Innovation Institute, which funds pilot-scale facilities accessible to small companies. Access is granted through project proposals.
The USDA BioPreferred Program, authorised under Section 9002 of the Farm Security and Rural Investment Act of 2002, requires federal agencies to buy designated bio-based products. Suppliers must register products in the USDA catalogue.

Market Segmentation

By Application
  • Therapeutics
  • Industrial Chemicals
  • Agricultural Biologicals
  • Food and Ingredients
  • Biofuels
By End User
  • Pharmaceutical and Biotechnology Companies
  • Chemical and Materials Manufacturers
  • Agriculture and Food Producers
  • Defence and Government Agencies
  • Academic and Research Institutes
By Technology
  • DNA Synthesis
  • Genome Editing
  • Metabolic Engineering
  • Cell-Free Systems
  • AI-Driven Protein Design

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Synthetic Biology - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Application Insights
4.1 Therapeutics
4.2 Industrial Chemicals
4.3 Agricultural Biologicals
4.4 Food and Ingredients
4.5 Others
Chapter 05 End User Insights
5.1 Pharmaceutical and Biotechnology Companies
5.2 Chemical and Materials Manufacturers
5.3 Agriculture and Food Producers
5.4 Defence and Government Agencies
5.5 Others
Chapter 06 Technology Insights
6.1 DNA Synthesis
6.2 Genome Editing
6.3 Metabolic Engineering
6.4 Cell-Free Systems
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Ginkgo Bioworks
7.2.2 Twist Bioscience
7.2.3 Codexis
7.2.4 Solugen
7.2.5 LanzaTech
7.2.6 Geno
7.2.7 Telesis Bio
7.2.8 Synthego
7.2.9 Ansa Biotechnologies
7.2.10 Asimov
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.